• Hypera published its 2Q26 earnings presentation on Aug. 7, 2026.
• Net revenue rose 8.5% to R$ 2.34 billion. Gross margin was 61.3%, up 1.7 pp.
• EBITDA from continuing operations increased 4.1% to R$ 754.5 million. Net earnings from continuing operations rose 15% to R$ 450 million.
• Operating cash flow was 103.5% of EBITDA. Interest on capital was approved at R$ 135.2 million.
• Highlights cited ANVISA approval of Semavy injectable semaglutide. The release also flagged a partnership in non-hormonal menopausal symptom treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hypera SA published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.